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Selecting short length nucleic acids localized 
in exosomes improves plasma EGFR mutation 
detection in NSCLC patients
Yoonjung Kim†, Saeam Shin†, Boyeon Kim and Kyung‑A Lee* 
Abstract 
Background: Exosomal nucleic acid (exoNA) is a feasible target to improve the sensitivity of EGFR mutation testing 
in non‑small cell lung cancer patients with limited cell‑free DNA (cfDNA) mutant copies. However, the type and size of 
target exoNA related to the sensitivity of EGFR mutation testing has not been explored extensively.
Methods: The type and size of target exoNA related to the sensitivity of EGFR mutation testing was evaluated using 
ddPCR. A total of 47 plasma samples was tested using short‑length exoTNA (exosomal DNA and RNA) and cfDNA.
Results: The sensitivity of short‑length exoTNA (76.5%) was higher than that of cfDNA (64.7%) for detecting EGFR 
mutations in NSCLC patients. In EGFR‑mutant NSCLC patients with intrathoracic disease (M0/M1a) or cases with 
low‑copy T790M, the positive rate was 63.6% (N = 7/11) and 45.5% (N = 5/11) for short‑length exoTNA and cfDNA, 
respectively. On average, the number absolute mutant copies of short‑length exoTNA were 1.5 times higher than 
that of cfDNA. The mutant allele copies (Ex19del and T790M) in short‑length exoTNA were relatively well preserved at 
4 weeks after storage. The difference (%) in absolute mutant allele copies (Ex19del) between 0 days and 4 weeks after 
storage was − 61.0% for cfDNA.
Conclusion: Target nucleic acids and their size distribution may be critical considerations for selecting an extraction 
method and a detection assay. A short‑length exoTNA (200 bp) contained more detectable tumor‑derived nucleic 
acids than exoDNA (~ 200 bp length or a full‑length) or cfDNA. Therefore, a short‑length exoTNA as a sensitive bio‑
marker might be useful to detect EGFR mutants for NSCLC patients with low copy number of the mutation target.
Keywords: Liquid biopsy, Extracellular vesicles, Circulating tumor DNA, Non‑small cell lung cancer, Epidermal growth 
factor receptor, ddPCR
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Background
The identification of driver and resistance mutations 
located in the tyrosine kinase domain of EGFR in a sub-
set of non-small cell lung cancer (NSCLC) is necessary 
to guide patient treatment options and to predict prog-
nosis [1–3]. The majority of EGFR genotyping is assessed 
through conventional tumor biopsy. However, this pro-
cess can frequently put the patient at risk and may miss 
portions of the tumor that are developing treatment 
resistance or have acquired new driver mutations due to 
tumor heterogeneity [4]. Thus, liquid biopsy is consid-
ered an alternative for detecting resistant-EGFR mutants 
in NSCLC patients undergoing tyrosine kinase inhibitor 
(TKI) therapy [5]. Circulating tumor DNA (ctDNA) is the 
most common source of nucleic acid for detecting EGFR 
and is already being implemented in clinical practice [6]. 
Current technologies, such as polymerase chain reaction 
(PCR)-based method and next-generation sequencing, 
have been developed to detect very low level of mutant 
ctDNA fraction in plasma [7, 8]. However, these plat-
forms show varying sensitivity depending on mutations 
and are not satisfactory enough to get reliable results 
in patients with scant T790M copies (< 0.01%) [9–11]. 
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Since tumor-derived nucleic acids rarely exist existing in 
patient’s plasma, pre-analytical steps, especially selecting 
target materials that harbored relatively abundant mutant 
alleles and extracted them using an appropriated method, 
are important to improve the sensitivity of EGFR test 
using patient’s plasma with low levels of mutant alleles.
Exosomes are endosome-derived small membrane-
bound vesicles that are released by different cell types 
[12]. Exosomes carry proteins, lipids, and nucleic acids, 
including DNAs and RNAs [13]. Growing evidence have 
indicated that exosomes are associated with tumor devel-
opment and metastasis [13, 14]. Exosomal nucleic acids 
(exoNA) containing tumor-derived nucleic acids were 
studied as a target for cancer mutation testing, and they 
also emerged as biomarkers for cancer diagnosis [15]. 
Moreover, they have recently been reported to be a sensi-
tive source for EGFR genotyping [16, 17]. To improve the 
sensitivity of detection in patients with limited mutant 
copies of cfDNA, such as those with early-stage NSCLC 
or intrathoracic disease (M0/M1a), exosomal nucleic 
acid (exoNA) might be a feasible alternative [15, 18]. To 
acquire high quality and quantity of exoNAs, the type and 
size of target exoNA should be considered when choos-
ing an extraction method; however, the type and size of 
target exoNA related to the sensitivity of EGFR mutation 
testing have not been extensively studied. In previous 
studies, the target of exoNA was exoDNA, exoRNA, or 
combined exoDNA/RNA [15–17, 19, 20]. Some studies 
targeted high molecular DNA from exosomes [17, 21], 
and other studies focused on fragmented DNA that local-
ized in exosomes [22]. In this study, we evaluated exoNAs 
to carefully determine a sensitive circulating biomarker 
in a plasma EGFR genotyping assay. Our results dem-
onstrate that short-length exoTNA (exosomal DNA and 
RNA) is a feasible target in patients with low-level EGFR 
mutant copies. We extracted short-length exoTNA using 
specific extraction kits that could enrich tumor-derived 
~ 200-bp-sized NAs. We then compared the ExoNAs 
and cfDNA isolated from NSCLC patients using droplet 
digital PCR (ddPCR) to detect EGFR mutations including 
exon 19 deletion (Ex19del), T790M, and L858R.
Materials and methods
Study design
ddPCR assays were performed with the PrimePCR™ 
ddPCR™ Mutation Detection Assay kit and Prime-
PCR™ ddPCR™ EGFR Exon 19 Deletions Screening Kit 
(Bio-Rad Laboratories, Hercules, CA, USA) (Additional 
file  1: Table  S1). We selected three hotspot mutations 
of Ex19del, L858R, and T790M. L858R and Ex19del are 
the most common forms of EGFR sensitizing mutations 
(85%) that are responsive for EGFR TKI treatment [23]. 
In case of progression on 1st generation TKI treatment, 
T790M mutation testing is recommended as acquired 
T790M mutation is the most common resistance mech-
anism (> 50%) that is responsive for 3rd generation TKI 
treatment [23, 24]. The limitation of detection (LOD) 
was determined as the lowest mutant concentration 
above the 95% confidence interval (CI) of the wild-type 
(WT) control, which was determined using a Poisson 
model (Additional file  1: Table  S2). Validation ddPCR 
was performed using Multiplex I cfDNA Reference 
Standard (Horizon Discovery, Cambridge, UK) (Addi-
tional file 1: Table S3). The ability to detect EGFR muta-
tion based on type of input nucleic acid (short-length 
exoTNA and a size range of exoDNA) was evaluated 
(Additional file  1: Figures  S1 and S2). Analytic perfor-
mance of isolated cfDNA and short-length exoTNA was 
evaluated using ddPCR. We assessed the influence on 
cfDNA levels and short-length exoTNA according to 
storage period.
Patients
From November 2017 to November 2018, 47 NCSLC 
patients were consented and enrolled. EGFR genotyp-
ing results (N = 46) from the corresponding tissue speci-
mens were obtained. Patients consented to the protocol 
approved by the Institutional Review Board of Gangnam 
Severance Hospital and Kangnam Sacred Heart Hospital. 
Plasma (2 mL) was collected from a total of 47 patients 
and stored at − 80 °C.
Nucleic acid extraction and cDNA synthesis
We extracted plasma cfDNA using the MagMAX Cell-
Free DNA Isolation Kit (Thermo Fisher Scientific, 
Waltham, MA, USA). Exosomes were isolated from 
plasma using ExoQuick™ (System Biosciences, Mountain 
View, CA, USA). Subsequently, short-length exoDNA 
and short-length exoTNA were isolated by MagMAX 
Cell-Free DNA Isolation Kit (Thermo Fisher Scien-
tific) and MagMAX™ Total Nucleic Acid Isolation Kit 
(Thermo Fisher Scientific), respectively. A size range of 
exoDNA was isolated by the QIAamp DNA Blood Mini 
Kit (Qiagen, Hilden, Germany). The concentration and 
size distribution of cfDNA and exoNA were assessed 
using a 2200 TapeStation Instrument (Agilent Technolo-
gies, Santa Clara, CA, USA) with the Agilent High Sen-
sitivity D1000 ScreenTape System and Genomic DNA 
ScreenTape System. The RNA yield and size distribu-
tion were analyzed using an Agilent 2100 Bioanalyzer 
with an RNA 6000 Pico kit (Agilent Technologies, Foster 
City, CA, USA). cDNA synthesis was performed using a 
SuperScript™ VILO™ cDNA Synthesis Kit (Invitrogen, 
Carlsbad, CA, USA).
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Validation of ddPCR
The ddPCR assays were performed with the Prime-
PCR™ ddPCR™ Mutation Detection Assay kit and 
PrimePCR™ ddPCR™ EGFR Exon 19 Deletions Screen-
ing Kit (Bio-Rad Laboratories) (Additional file  1: 
Table  S1). We used cfDNA from Multiplex I cfDNA 
Reference Standards (Horizon Discovery) that included 
wild-type cfDNA with mutant allele frequencies of 
5%, 1%, and 0.1%. cfDNA Reference Standards (Hori-
zon Discovery) with 0.1% mutant allele was serially 
diluted to wild-type cfDNA for analytical sensitivity of 
the ddPCR assay (Additional file  1: Table  S3). Healthy 
control samples and DNA-free samples were also ana-
lyzed (Additional file  1: Table  S2) [25, 26]. Amplifica-
tions were carried out in a reaction volume of 20 μL on 
a QX100 Droplet Digital PCR System (Bio-Rad). The 
20 μL PCR mix was composed of 10 μL Bio-Rad Super 
mix TaqMan, 1–2 μL of each amplification primer/
probe mix, and 8–9  μL NAs. Thermal cycling com-
prised an initial denaturing and polymerase hot-start 
activating step of 10 min at 95 °C, followed by 40 cycles 
of 95  °C for 30 s and 55  °C for 60 s. Results were ana-
lyzed with QuantaSoft v.1.7.2 software (Bio-Rad) and 
reported as copies per milliliter of plasma.
Effects of storage on cfDNA and short‑length exoTNA 
concentrations
Samples from two patients with EGFR mutation and 
three normal controls were collected in  K2 EDTA tubes. 
Immediately separated plasma was aliquoted into three 
tubes per sample and stored at − 80 °C. We assessed the 
influence of storage period on cfDNA levels and short-
length exoTNA extracted at different time points (0, 14, 
and 28 days).
Data analysis
Quantification of the number of target DNA molecules in 
the reaction is achieved by counting the number of posi-
tive and negative droplets. The LOD was determined as 
the lowest mutant concentration above the 95% CI of the 
WT control. The 95% CI was determined using a Poisson 
model and CLSI EP17-A2 [26, 27]. Details are described 
in Additional file  1: Table  S2. Assays were considered 
“positive” if the measured event rate was ≥ 2 events/assay 
and “negative” if the event rate within a gated region was 
< 2 events/assay.
Statistical analyses
Statistical analysis was performed using R (version 3.5.2, 
http://www.r-proje ct.org) and MedCalc software (https 
://www.medca lc.org/). Data are presented using a 95% CI 
and 2-sided P value.
Results
Patient characteristics
The patients’ characteristics are described in Table  1. 
Patients had a median age of 73  years (range, 
52–85  years), and 19 patients (40.4%) were female. The 
adenocarcinoma, squamous cell carcinoma, and other 
histologic types numbered 32 (68.1%), 9 (19.1%), and 6 
(12.8%), respectively. Stage IV was dominant (N = 31, 
66.0%), and other stages (I–III) represented 34.0% of total 
patients. Patients with intrathoracic metastatic disease 
(M0/M1a) accounted for 51.0% (Table 1).
Assessment of ddPCR assay sensitivity
The analytical sensitivity of the ddPCR assay was evalu-
ated using spiked samples with mutant allele frequen-
cies of 1%, 0.1%, 0.02%, 0.01%, and 0.005% (Additional 
file  1: Table  S3). The expected copy number of mutant 
alleles (1–32 copies) spiked into the wild-type alleles 
Table 1 Baseline characteristics of patients
Other not otherwise specified, TKI tyrosine kinase inhibitor
a Results are expressed as median (range) or number (%)
b According to the 8th TMN edition, M1a indicates lung metastases or pleural/
pericardial malignant effusion or nodules; M1b indicates a single metastatic 
lesion in a single distant organ; M1c indicates multiple lesions in a single organ 
or multiple lesions in multiple organs
Characteristic All patients (N = 47)a
Age (years) 73 (52–85)
Gender
 Female 19 (40.4%)
 Male 28 (59.6%)
Histologic type
 Adenocarcinoma 32 (68.1%)
 Squamous cell carcinoma 9 (19.1%)
 Other 6 (12.8%)
Tumor stage
 I 5 (10.6%)
 II 2 (4.3%)
 III 9 (19.1%)
 IV 31 (66.0%)
M  categoryb
 M0 16 (34.0%)
 M1a 8 (17.0%)
 M1b 3 (6.4%)
 M1c, single organ 3 (6.4%)
 M1c, multi organs 17 (36.2%)
Chemotherapy
 TKI‑naïve 43 (91.5%)
 TKI‑treated 4 (8.5%)
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(2000–20,000) and the actual copy number of mutant 
alleles observed in the spiked samples are shown in Addi-
tional file 1: Table S3. An ultra-rare mutation (1 copy in 
a spiked sample) as low as 0.007–0.008% was success-
fully detected by the ddPCR assay. However, when we 
considered 2 copies/mL as a threshold for a positive 
result, Ex19del, L858R, and T790M were detected even 
at fractional abundance of 0.03%, 0.013%, and 0.018%, 
respectively (Additional file  1: Table  S3). The limit of 
blank (LOB) defined by the frequency of positive droplets 
measured in DNA-free samples and the standard devia-
tion (SD) of healthy controls were used to determine the 
lower LOD. Additional file 1: Table S2 shows the raw data 
for LOB analysis and LOD.
Comparison between cfDNA and size‑selectively extracted 
exoNAs
To elucidate the components of exoNAs that were 
related to the sensitivity of EGFR mutation test-
ing, pooled plasma samples with Ex19del mutation 
were used. Isolated cfDNA, short-length exoNAs 
(DNA and TNA), and a full-length exoDNA includ-
ing low and high molecular weight nucleic acids were 
co-isolated (Additional file  1: Figure S1). We assessed 
tumor-derived NAs to be more abundant in the short-
length NAs (~ 200 bp long) than the full-length exoD-
NAs in exosomes (Additional file 1: Figures S1 and S2). 
Especially, short-length exoTNA is superior to other 
nucleic acid materials (cfDNA, short-length exoDNA, 
and full-length exoDNA) for detecting EGFR mutant 
alleles (Additional file  1: Figure S1). Quantity and size 
of short-length NAs were further confirmed by Bioan-
alyzer results, which also showed a major peak at less 
than ~ 200 bp long (data not shown).
Mutant allele ratio between cfDNA and short‑length 
exoNA
We evaluated the quantity of wild-type and mutant 
allele copies at cfDNA and short-length exoNAs (DNA 
and TNA) in spiked samples from NSCLC patients har-
boring EGFR mutation. The mutant allele ratio (short-
length exoTNA/cfDNA) ranged from 1.2 to 2.5, and 
the mutant allele ratio of short-length exoDNA/cfDNA 
ranged from 0.0 to 1.0 (Table 2). Short-length exoTNA 
showed the largest absolute number of mutant allele 
copies compare to cfDNA and short-length exoDNA. 
However, due to the abundance of wild-type allele cop-
ies in short-length exoTNA, the mutant allele fraction 
(%) of cfDNA was generally higher than that of short-
length exoTNA. Both cfDNA and short-length exoTNA 
are considered good materials for detection of tumor-
derived mutant alleles (Table 2).
We performed ddPCR using 250, 500, 750, and 
1000  μL plasma to assess the proper plasma volume 
for sensitive detection and monitoring. The amount of 
input plasma volume determined number of mutant 
allele copies in cfDNA and exoNAs. The mutant allele 
ratio between cfDNA and short-length exoTNA was 
relatively higher in a small input volume (250 μL) 
(Additional file 1: Figure S1).
Table 2 Comparison between cfDNA and short-length exosomal nucleic acids
cfDNA cell-free DNA, exoDNA exosomal DNA, exoTNA exosomal DNA and RNA, Ex19del exon 19 deletion, N.A not available
a Spiked samples with pooled plasma from patients harboring mutations in EGFR (Ex19del, L858R, and T790M). cfDNA and short-length exoDNA were extracted using 
MagMAX Cell-Free DNA Isolation Kit. Short-length exoTNA was extracted using MagMAX™ Total Nucleic Acid Isolation Kit
Samplea Target Mutant 
events
Wild‑type 
events
Fraction (%) Mutant allele ratio Wild‑type allele ratio
exoDNA/
cfDNA
exoTNA/
cfDNA
exoDNA/
cfDNA
exoTNA/
cfDNA
Spiked sample 1 (Ex19del) cfDNA 20 418 4.78 0.5 1.2 0.6 2.7
Short‑length‑exoDNA 9 270 3.33
Short‑length‑exoTNA 24 1138 2.11
Spiked sample 2 (L858R) cfDNA 1 156 0.64 1 2 0.8 2.6
Short‑length‑exoDNA 1 131 0.76
Short‑length‑exoTNA 2 399 0.5
Spiked sample 3 (L858R) cfDNA 2 38 5.26 0 2.5 0 6
Short‑length‑exoDNA 0 1 0
Short‑length‑exoTNA 5 228 2.19
Spiked sample 3 (T790M) cfDNA 0 97 0 N.A. N.A. N.A. N.A.
Short‑length‑exoDNA 6 89 6.74
Short‑length‑exoTNA 8 307 2.61
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Quantification of short‑length exoTNA and cfDNA 
in clinical samples
Short-length exoNA and cfDNA were extracted from 
equal volumes (1  mL) of plasma samples from 47 
patients. Among them, 7 samples were not available for 
NA quantification due to lack of volume. The concentra-
tions of short-length exoTNA and cfDNA are depicted in 
Fig.  1. The median concentration levels of short-length 
exoTNA and cfDNA were 11.9  ng/mL and 6.1  ng/mL, 
respectively, and there was not a significant difference 
between short-length exoTNA and cfDNA (P = 0.6978).
Comparison of EGFR mutation status in NSCLC patients
Plasma samples from 47 patients were tested with short-
length exoTNA and cfDNA using ddPCR, and each sam-
ple was analyzed for Ex19del, L858R, and T790M. Of the 
141 measurements (3 mutant sites per each patient), 17 
and 124 measures were classified as true positives (TP) 
and true negatives (TN), respectively, compared to tis-
sue biopsy (Table 3). Seventeen TPs were detected from 
15 patients; among them, 2 patients harbored both acti-
vating and resistant EGFR mutations (Fig.  2b). Three 
patients harboring T790M or L858R were only detected 
in plasma samples using the  cobas® EGFR Mutation Test 
v2 not in tissue samples. These EGFR mutations were also 
detected in cfDNA or/and short-length exoTNA up to a 
9.5% mutant allele fraction (%). Therefore, we regarded 
these three mutations as “TP” results. The sensitivity of 
short-length exoTNA (76.5%) was higher than that of 
cfDNA (64.7%) for activating/resistant EGFR mutations 
(Table  3). We also found that 46.7% (7/15) of TP cases 
were from patients with intrathoracic (M0/M1a) disease, 
and 53.3% (8/15) were from patients with M1b/M1c dis-
ease. In false negative (FN) results, 9 FNs (short-length 
exoTNA, 4 samples; cfDNA, 5 samples) were from five 
patients with M0/M1a. One FN case (cfDNA, 1 sample) 
was from a patient who progressed under treatment with 
an EGFR-TKI (Fig. 2b). The specificity of EGFR genotyp-
ing was 100.0% and 97.6% for short-length exoTNA and 
cfDNA, respectively (Table  3). Two false-positives (FPs) 
were found only in cfDNA with two events of the mutant 
allele in ddPCR. The accuracy of EGFR genotyping was 
slightly higher with short-length exoTNA (97.2%) than 
with cfDNA (93.6%) (Table  3). The mean mutant allele 
ratio (short-length exoTNA / cfDNA) was 1.5 and ranged 
from 0.8 to 6.6 (Fig. 2a, b). The main peak of nucleic acids 
of cfDNA and short-length exoTNA was ~ 200 bp long in 
EGFR mutated NSCLC patient plasma (Fig. 2c).
Effects of storage at cfDNA and short‑length exoTNA
We determined whether the storage duration of cfDNA 
and short-length exoTNA could affect the detection 
of EGFR mutations. The median wild-type allele ratio 
(short-length exoTNA/cfDNA) of three normal con-
trols was 0.9, 1.2 and 0.7 at 0 days, 2 weeks, and 4 weeks, 
Fig. 1 Nucleic acid concentration plots from short‑length exoTNA 
and cfDNA. The y‑axis indicates the concentration of nucleic acids in 
nanograms per milliliter, and the x‑axis indicates sample materials. 
Black horizontal bars indicate median with interquartile range. The P 
value was calculated using paired t test
Table 3 Comparison of the EGFR mutation status between tumor tissue and plasma in NSCLC patients (N=47)
NSCLC non-small cell lung cancer, TP true positive, TN true negative, CI confidence interval
a Tissue EGFR genotyping results were considered ‘true positive’ or ‘true negative.’ Three cases for which tissue EGFR was negative showed positive results using the 
 cobas® EGFR Mutation Test v2. These results were regarded as ‘true positive.’
EGFR genotype TP and  TNa cfDNA Short‑length exoTNA
Mutant type Wild‑type Mutant type Wild‑type
Mutant type 17 11 6 13 4
Wild‑type 124 3 121 0 124
Sensitivity,% (95% CI) 64.7% (38.3–85.8%) 76.5% (50.1–93.2%)
Specificity, % (95% CI) 97.6% (93.1–99.5%) 100.0% (97.1–100.0%)
Accuracy, % (95% CI) 93.6% (88.2–97.0%) 97.2% (92.9–99.2%)
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respectively. The average wild-type allele ratio in two 
patients was 1.8, 3.3, and 2.3 at 0  days, 2  weeks, and 
4 weeks, respectively. The average mutant allele ratio was 
1.6, 6.6, and 2.8 at 0 days, 2 weeks, and 4 weeks, respec-
tively. The T790M mutant allele ratio showed a fivefold 
increase after 2 weeks of storage, and this mutant allele 
ratio at 4 weeks later was similar to that of day 0 (Fig. 3a). 
The mutant allele copies (Ex19del and T790M) in short-
length exoTNA were relatively well preserved after 
4  weeks (Fig.  3b). The difference (%) between Ex19del 
mutant allele fraction (%) and that of the absolute mutant 
allele copies between 0 days and 4 weeks after storage was 
− 21.3% and − 61.0%, respectively, in cfDNA (Fig. 3b).
Discussion
To improve the sensitivity of low levels of plasma cfDNA, 
there has been a focus on enriching for cfDNA fragments 
on the basis of length [28–30]. It has been reported that 
mutant alleles occur more commonly in shorter frag-
ments of cfDNA in lung cancer patients [30]. However, 
the size of NA in exosomes that might contain relatively 
high tumor-derived NAs remains unclear. According to 
Hur et  al., EGFR-mutant DNA is mainly distributed as 
high-molecular weight DNA (~ 10 kb) in exosomes from 
plasma and bronchoalveolar lavage fluid [17]. However, 
they only evaluated NAs of exosomes using an extraction 
kit for full-length DNA. Fernando et  al. demonstrated 
that fragmented DNAs of ~ 200 bp in size comprised the 
majority of NAs localized in exosomes [22]. By compar-
ing different sizes of exoNAs, we observed that the EGFR 
mutant alleles were more enriched in short-length NAs 
(~ 200  bp long) than in high-molecular weight DNA in 
exosomes (Additional file 1: Figures S1 and S2).
Recent studies have shown that using single-step isola-
tion of combined exosomal RNA/DNA and cfDNA is a 
highly sensitive method for detecting EGFR mutations in 
NSCLC patient plasma [16, 18]. However, the target NAs 
and their size have not been clearly elucidated. We deter-
mined that short-length exoTNA is superior to other 
nucleic acid materials (cfDNA, short-length exoDNA and 
full-length exoDNA) for mutant allele detection (Table 2 
and Fig.  2). When comparing short-length exoTNA to 
cfDNA, the average number of mutant copies is 1.5 times 
higher for short-length exoTNA (Fig.  2a). Furthermore, 
the sensitivity of detecting EGFR mutations using short-
length exoTNA is higher than that using cfDNA (76.5% 
vs. 64.7%) (Table 3).
Analysis of cfDNA from blood could be an alterna-
tive method for identifying EGFR mutations in NSCLC 
patients. However, detectable mutant copies in cfDNA 
are too few to increase false negative rate in EGFR-
mutated NSCLC. Patients with low T790M copy number 
Fig. 2 Comparison between short‑length exoTNA and cfDNA in plasma from NSCLC clinical samples. a, b The mutant allele ratio (short‑length 
exoTNA/cfDNA) and mutant allele copies/mL in NSCLC patients harboring EGFR mutation. c The size distribution of nucleic acids in cfDNA and 
short‑length exoTNA in plasma from EGFR mutated NSCLC patients
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(< 10 copies/mL) have a similar response to osimertinib 
to patients with a higher T790M copy number (≥ 10 cop-
ies/mL) [31]. Furthermore, an actual number of patients 
with low T790M copy number (< 10 copies/mL) was 
fourfold higher than the number of patients with a higher 
T790M copy number (≥ 10 copies/mL) [32]. Around half 
of cases in the present study harboring plasma EGFR 
mutation also had low mutant allele copies (< 10  cop-
ies/mL) (Fig.  2a, b). In EGFR-mutant NSCLC patients 
with intrathoracic disease (M0/M1a) or cases with low 
copy T790M, the positive rate was 63.6% (N = 7/11) and 
45.5% (N = 5/11) in short-length exoTNA and cfDNA, 
respectively (Fig.  2b). These data demonstrate that the 
increased numbers of detectable EGFR mutant copies 
obtained from extraction of exoTNA could influence the 
sensitivity of ddPCR-based EGFR mutation test for cases 
with low copy EGFR mutants.
Short-length exoTNA and cfDNA showed generally 
good concordance with tissue EGFR results. Despite 
the small number of studied samples, 17.6% of EGFR 
mutants (N = 3/17) were detected in plasma samples 
where the mutation was not detected in tissue previously. 
The false-negative results of tissue might be caused by 
tumor heterogeneity [33] or failure to obtain adequate 
specimen. This highlights the feasibility of blood-based 
EGFR testing in diagnosis and monitoring of cancer.
To evaluate the influence of storage period on cfDNA 
and short-length exoTNA for assay performance, we 
compared cfDNA and exoTNA from plasma at dif-
ferent time points (0, 14, and 28  days). When plasma 
was stored at − 80 °C for 4 weeks, the amounts of both 
T790M and Ex19del mutant copies in short-length 
exoTNA remained stable; however, in cfDNA, Ex19del 
mutant copies decreased by up to 61%. In the previ-
ous study, storage at − 20 °C barely impacted the over-
all amounts of exosomal miRNAs for at least 5  years 
[34]. The stability of exoTNA could be explained by 
the mechanism by which lipid bilayer membrane coat-
ing protects internal DNA and RNA [21]. The amounts 
and integrity of cfDNA could be affected by storage 
duration. Storing plasma samples at − 80 °C is recom-
mended until further processing of cfDNA isolation is 
implemented [35]. Following the recommendation, a 
majority of laboratories have stored plasma at − 80 °C 
[36]. Barrett et al. demonstrated the stability of cfDNA 
from plasma samples stored at − 80  °C for up to 
2 weeks [35]. However, according to our data, the stor-
age period can influence the stability of cfDNA that is 
stored more than 2  weeks. Therefore, when perform-
ing the EGFR assay, the storage duration of plasma 
should be considered. Given the limited sample size 
we used, future study should be performed to confirm 
the effects of − 80 °C storage on the amount and integ-
rity of cfDNA and short-length exoTNA.
Fig. 3 Effects of storage on cfDNA and short‑length exoTNA. a Allele ratio (short‑length exo/cfDNA) change in two patients with EGFR mutation 
and three normal controls. In normal controls, only the wild‑type allele ratio (short‑length exo/cfDNA) is depicted. b The change in mutant allele 
fraction (%) in short‑length exoTNA and cfDNA according to storage time
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Conclusion
Target nucleic acids and their size distribution might 
be critical considerations for selecting an extrac-
tion method and a detection assay. In this study, we 
mainly determined the characteristics of an effective 
target component in exosomes. A shorter exoTNA 
with 200  bp length contained more detectable tumor-
derived nucleic acids than exoDNA (~ 200 bp length or 
full-length) or cfDNA. Blood-based cancer diagnostic 
testing is a promising tool not only for early diagnosis 
of cancer, but also for patient stratification and longitu-
dinal monitoring of residual tumors [5, 37, 38]. There-
fore, short-length exoTNA as a sensitive biomarker 
might be useful to detect EGFR mutants for NSCLC 
patients with low copy numbers of the mutation target.
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